Levosimendan Fresenius Kabi

Levosimendan, the active ingredient in Levosimendan Fresenius Kabi, is a calcium sensitizer presented as an injectable solution for intravenous use. It enhances cardiac contractility and promotes vasodilation, providing therapeutic benefit in acute decompensated heart failure for adult patients who require rapid hemodynamic support in critical care settings.

GNH USA supplies Levosimendan Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide, ensuring quality‑assured product availability and regulatory compliance across global markets through robust logistics networks.

Levosimendan is a calcium sensitizer used in the management of acute heart failure.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. Low‑output syndrome after cardiac surgery: provides temporary hemodynamic support. Severe chronic heart failure (inotropic support): offers short‑term improvement in ventricular performance.

Levosimendan may be associated with several adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Dizziness: feeling of light‑headedness. - Arrhythmia: non‑life‑threatening rhythm changes.

Serious or Rare Side Effects: - Severe hypotension: may require intervention. - Ventricular arrhythmia: potentially life‑threatening. - Myocardial ischemia: chest pain or ECG changes. - Allergic reaction: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests. - Thrombocytopenia: reduced platelet count.

Levosimendan requires careful monitoring and specific safety measures.

Monitor blood pressure: watch for significant hypotension. Observe cardiac rhythm: detect arrhythmias early. Use cautiously in renal impairment: adjust therapy as needed. Avoid in severe hypotension: contraindicated when systolic pressure is very low. Adjust dose in hepatic dysfunction: liver disease may affect drug clearance. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medications that affect cardiovascular function.

Major Interactions (Avoid): - Concurrent vasodilators: may cause profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase levosimendan exposure.

Moderate Interactions (Monitor Closely): - Other inotropes (e.g., dobutamine): additive effects on contractility. - Diuretics: may enhance volume depletion. - Beta‑blockers: may blunt desired inotropic response. - Nitrates: combined vasodilatory effect. - ACE inhibitors or ARBs: potential for additive blood pressure reduction.